MedTrace Logo

Assessment of Grazax® Treatment Compliance

NCT00293046 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2008-09-30

No results posted yet for this study

Summary

This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).

Conditions

  • Allergy

Interventions

BIOLOGICAL

ALK Grass tablet - use of compliance device

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Kim Simonsen, MD · ALK-Abelló A/S

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2006-09-30
Completion
2007-10-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293046 on ClinicalTrials.gov